Related Experiment Video

Updated: Jun 16, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors

Gabriella Traquandi1, Marina Ciomei, Dario Ballinari

  • 1Nerviano Medical Sciences Srl, Business Unit Oncology, Viale Pasteur 10, 20014 Nerviano, MI, Italy. gabriella.traquandi@nervianoms.com

Journal of Medicinal Chemistry
|February 10, 2010
PubMed

Insights

Researchers developed novel pyrazolo[4,3-h]quinazoline compounds targeting cyclin-dependent kinases (CDKs) to treat cancer. Compound 59 shows high potency and oral bioavailability, demonstrating significant efficacy in ovarian cancer models.

Area of Science:

  • Medicinal Chemistry
  • Oncology
  • Molecular Biology

Background:

  • Cancer is characterized by uncontrolled cell proliferation due to cell cycle dysregulation.
  • Targeting cyclin-dependent kinases (CDKs) and cyclins (Cy) offers a promising strategy for novel antitumor agents.

Purpose of the Study:

  • To develop novel pyrazolo[4,3-h]quinazoline derivatives as potent CDK inhibitors.
  • To identify compounds with improved solubility, pharmacokinetic properties, and in vivo efficacy.

Main Methods:

  • Synthesis and chemical modification of pyrazolo[4,3-h]quinazoline compounds.
  • In vitro evaluation of CDK inhibitory activity and anti-proliferative effects on cancer cells.
  • In vivo efficacy studies using an ovarian carcinoma xenograft model.

Main Results:

  • Several novel compounds demonstrated enhanced CDK inhibition and anti-tumor activity.
  • Compound 59 exhibited high potency, oral bioavailability, and significant in vivo efficacy.
  • Compound 59 showed promising mechanisms of action against cancer cell lines.

Conclusions:

  • Compound 59 is a potent, orally bioavailable CDK inhibitor with significant anti-cancer potential.
  • The pyrazolo[4,3-h]quinazoline scaffold is a valuable platform for developing new antineoplastic agents.
  • Further investigation of compound 59 as an antineoplastic agent is warranted.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...